EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency

Miguel A Escobar iD, Kaan Kavakli iD

Haemophilia · 2024

DOI: 10.1111/hae.14894 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Haemophilia, 2024. Verfasst von Miguel A Escobar und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas,…. Hauptthemen laut MEDLINE: Factor X, Factor X Deficiency. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bio Products Laboratory (Elstree, United Kingdom).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hereditary factor X (FX) deficiency (HFXD) is an autosomal recessive rare bleeding disorder that leads to defects in the FX protein. Depending on the degree of deficiency, patients may be at risk of life‐threatening bleeding episodes. Historical treatments for FX deficiency include prothrombin complex concentrates, which can increase the risk of thrombosis, and fresh frozen plasma, which can cause volume overload and transfusion reactions. Plasma‐derived FX (pdFX), a single‐factor, high‐purity, high‐potency human FX treatment, was approved in 2015 in the United States and in 2016 in Europe for on‐demand treatment and prophylaxis of bleeding episodes and perioperative management of patients with HFXD.

Methods

Five studies that examined the use of pdFX in patients with mild (plasma FX activity [FX:C] ≥5 IU/dL), moderate (FX:C ≥1 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XFactor X DeficiencyHumansProspective StudiesRetrospective StudiesHemorrhagePlasma

Stichwörter der Autor:innen

factor X deficiencyplasma-derived factor Xprothrombin complex concentraterare blood disordersevere bleeding episode

Substanzen

Factor X

Autor:innen und Institutionen

  • University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
  • Department of Pediatrics, Division of Hemato-Oncology, Ege University Faculty of Medicine, İzmir, Turkey.

ORCID-Profile: Miguel A Escobar, Kaan Kavakli

Förderung

  • Bio Products Laboratory (Elstree, United Kingdom)

Zitieren

APA

Escobar, M. A., & Kavakli, K. (2024). Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency. Haemophilia. https://doi.org/10.1111/hae.14894

Vancouver

Escobar MA, Kavakli K. Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency. Haemophilia. 2024. doi:10.1111/hae.14894

BibTeX
@article{Escobar2024,
  author = {Escobar, Miguel A and Kavakli, Kaan},
  title = {Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.14894}
}
Kostenlos starten →